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Abstract 
Background: The carotid artery intima-media thickness (CIMT) has been used as a predictor of cardiovascular events, 
but it remains unclear whether CIMT can change over the short term. We evaluated changes of CIMT in patients with 
diabetes during admission to hospital for 2 weeks.
Methods: A total of 279 inpatients with diabetes aged 61 ± 14 years were recruited. They were on treatment with 
insulin and/or oral agents, excluding drugs that influence the fluid balance and hemodynamics. CIMT was measured 
on the day after admission and on the day before discharge, and the association of ΔCIMT (calculated by subtracting 
the baseline value from that on the day before discharge) with clinical factors was evaluated.
Results: Based on the reported annual increase of CIMT (0.04 mm/year), the patients were divided into three groups, 
in which CIMT increased [I: ΔCIMT ≥ 0.04 mm, n = 64, ΔCIMT = 0.077 ± 0.048 (mean ± SD)], CIMT decreased (D: 
ΔCIMT ≤ −0.04 mm, n = 51, ΔCIMT = −0.090 ± 0.086), or CIMT was unchanged (N: −0.04 mm < ΔCIMT < 0.04 mm, 
n = 164, ΔCIMT = 0.002 ± 0.022). Binary logistic regression analysis showed that baseline CIMT and hemoglobin (Hb) 
were positively correlated, while Hb on the day before discharge was negatively correlated, with a decrease of CIMT. 
In contrast, baseline HbA1c and Hb were negatively correlated, while Hb on the day before discharge was positively 
correlated, with an increase of CIMT.
Conclusions: CIMT may show plasticity in patients with diabetes and can change even after short-term treatment of 
hyperglycemia for 2 weeks.
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Background
The carotid artery intima-media thickness (CIMT) is an 
ultrasound biomarker of subclinical atherosclerosis that 
predicts events related to cardiovascular disease (CVD). 
The Kuppio ischemic heart disease study first reported an 
association of CIMT with future coronary artery events 
[1]. Subsequently, various large-scale prospective studies 
have confirmed the usefulness of CIMT for assessing the 
risk of CVD events [2–4]. CIMT has been reported to be 
larger in diabetic patients than in non-diabetic subjects 
[5]. Previous studies have also shown that the annual rate 
of CIMT increase in Japanese patients with type 2 diabe-
tes is about 0.04 mm [6–8]. Previous intervention studies 
have demonstrated a decrease of CIMT or attenuation of 
its progression in patients with diabetes after treatment 
of hyperglycemia [7, 8]. These changes of CIMT were 
observed after at least 6 months, but lipid-lowering inter-
vention studies using statins for 6–8  weeks have found 
a decrease of CIMT [9, 10], suggesting that more rapid 
change may be possible.
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CIMT measures both the intimal and medial layers 
of the carotid artery, with the former comprising the 
endothelial cell layer plus the subendothelial space and 
the latter consisting of smooth muscle cells with inter-
stitial fibrous tissue. Recent studies have shown that the 
mechanism of medial thickening may involve remodeling 
of smooth muscle cells by hyperplasia and/or hypertro-
phy due to hemodynamic changes caused by increased 
stroke volume or glucose-related arterial stiffness [11]. 
Severe hyperglycemia is generally accompanied by dehy-
dration due to persistent osmotic diuresis. Thus, hemo-
dynamics may change rapidly during treatment of either 
severe or mild hyperglycemia in patients with diabetes. 
Accordingly, we hypothesized that CIMT may show 
short-term alterations in response to such hemodynamic 
changes. To investigate this hypothesis, we evaluated 
short-term changes of CIMT in patients with diabetes 
from the day after admission for treatment of hyperglyce-
mia to the day before discharge (about 14 days later).
Methods
Subjects
This was a cross-sectional study carried out at St. Mari-
anna University Hospital (Kawasaki, Japan). A total of 
312 consecutive patients admitted for treatment of type 
1 or type 2 diabetes between April 2007 and January 2015 
were recruited. All of the patients were admitted for ini-
tial diabetes education and improvement of glycemic 
control under a program provided by the Japanese health 
system, and none of them were hospitalized for acute 
metabolic complications (e.g. diabetic ketoacidosis). 
Patients with malignancy, severe heart failure (NYHA 
classes II–IV), severe acute or chronic kidney disease 
(CKD stages 4 and 5), liver cirrhosis or active hepatitis, 
a history of steroid therapy, endocrine disease, and preg-
nancy or breast-feeding were excluded, as were any other 
patients judged to be unsuitable for this study. Patients 
were treated with insulin and/or oral hypoglycemic 
agents, but the following medications were not used to 
avoid an influence on the fluid balance and hemodynam-
ics: thiazolidinediones, sodium glucose co-transporter 
2 inhibitors, angiotensin-converting enzyme inhibitors, 
angiotensin-II receptor blockers, and diuretics.
Ethics approval and consent to participate
The study protocol was approved by the ethics commit-
tee of St. Marianna University, and all patients provided 
written informed consent to participate.
Data collection
In all patients, the height, body weight (BW), blood pres-
sure (BP), and CIMT were determined at baseline. Blood 
samples were collected in the morning on the day after 
admission following an overnight fast (at least 12  h). 
Fasting plasma glucose (FPG) was measured by the 
hexokinase UV method, hemoglobin A1c (HbA1c) was 
determined by the latex aggregation method, and serum 
glycated albumin (GA) was assayed by an enzymatic 
method using an albumin-specific protease (ketoamine 
oxidase) and an albumin assay reagent (Lucica GA-L, 
Asahi Kasei Pharma, Tokyo, Japan). Plasma lipids (total 
cholesterol, triglycerides, HDL-cholesterol, and LDL-
cholesterol) were determined by enzymatic methods. 
The daily glucose profile was evaluated by 10-point self-
monitoring of blood glucose (SMBG) using a onetouch 
ultra blood glucose monitor (Life Scan, Milpitas, CA, 
USA). On the morning of the day before discharge (about 
10–14 days after admission), the BW, BP, and CIMT were 
measured, blood samples were obtained, and 10-point 
SMBG was repeated under the same conditions.
Measurement of CIMT
Assessment of CIMT was performed by a single 
trained sonographer (SY, a Registered Medical Sonog-
rapher certified by the Japan Society of Ultrasonics 
in Medicine) using the same ultrasonography device 
(LOGIQe, GE Yokokawa Medical, Tokyo, Japan) and 
a 10  MHz linear transducer with high axial resolu-
tion in the order of 0.01  mm. Patients were examined 
in the supine position. B-mode scanning of the com-
mon carotid artery (CCA) was performed bilaterally 
in two different longitudinal projections (anterior-
oblique and lateral), and 20 mm long images of the far 
wall of the CCA were obtained from the origin of the 
carotid bulb to a point 20  mm proximal. Then CIMT 
was automatically determined from these images by 
using analytical software (Intimascope 5.01R, Soft 
Medical Co. Ltd., Tokyo, Japan) [12–14], which was 
designed to divide a 2 cm length of the CCA into 330 
points for CIMT measurement and calculate the aver-
age of the 330 values thus obtained. We averaged the 
four CIMT values thus obtained (from the two projec-
tions on the right and left sides) to calculate the mean 
CIMT for use in subsequent analyses. The change of 
the mean CIMT (ΔCIMT) was calculated by subtract-
ing the baseline mean CIMT from that determined 
on the day before discharge. Thus, a positive value 
means CIMT gets larger (worsens) and a negative value 
means CIMT gets smaller (improves). It was previously 
reported that the annual rate of CIMT increase in Japa-
nese patients with type 2 diabetes is about 0.04  mm 
[6–8]. Based on this finding, we classified the patients 
into three groups, in which CIMT increased (group 
I, ΔCIMT  ≥  0.04  mm), CIMT decreased (group D, 
ΔCIMT ≤ −0.04 mm), or CIMT was unchanged (group 
N, −0.04 mm < ΔCIMT < 0.04 mm).
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Statistical analysis
Results are expressed as the mean ± SD. Comparison of 
mean values among the three groups was done by uni-
variate ANOVA followed by a post hoc Tukey multiple 
comparison test. To assess the relationship of clinical fac-
tors with an increase or decrease of CIMT, binary logis-
tic regression analysis was performed. All analyses were 
done with SPSS ver. 21.0 software (IBM, Tokyo, Japan), 
and statistical significance was defined as P < 0.05.
Results
A total of 279 patients completed the study, while 33 
patients dropped out because they were discharged from 
hospital earlier than 10 days. Baseline clinical character-
istics of the subjects are displayed in Table 1. The three 
groups showed no differences of gender, age, and body 
mass index (BMI). In group D, CIMT and FPG were 
both higher than in group N or group I. HbA1c and GA 
were also higher in group D than in group I, while GA 
was lower in group I than in group N. The other baseline 
clinical factors did not differ among the three groups.
Changes of the daily glucose profile from baseline to the 
day before discharge are displayed in Fig.  1. Mean SMBG 
values were lower at all points on the day before discharge 
in each group, and no differences were observed at the same 
time points among the three groups. Comparison of clini-
cal factors between baseline and the day before discharge is 
shown in Table 2. In group I, CIMT was larger than in group 
N on the day before discharge. ΔCIMT was larger in group I 
than in group N, while it showed a negative value (decrease 
of CIMT) in group D (0.077 ±  0.049, 0.002 ±  0.022, and 
−0.090 ± 0.086 mm, respectively, p < 0.001). The Hb, hem-
atocrit (Ht), and area under the daily glucose profile curve 
(AUCglu) were not different among the three groups either 
Table 1 Baseline clinical characteristics of the patients
Values are presented as the mean ± SD or number (%)
I increased IMT group, N unchanged IMT group, D decreased IMT group, Ht hematocrit
* p < 0.01 vs N, ** p < 0.01 vs I, *** p < 0.05 vs I
Group Total I N D p value
n (%) 279 (100) 64 (22.9) 164 (58.8) 51 (18.3)
Women (%) 117 (42) 29 (45) 67 (41) 21 (41) 0.823
Age (years) 60.6 ± 14.3 61.6 ± 13.5 59.6 ± 15.2 62.6 ± 11.7 0.333
BMI (kg/m2) 25.9 ± 5.2 27.3 ± 5.4 25.3 ± 5.2 26.0 ± 4.2 0.238
CIMT (mm) 0.737 ± 0.154 0.726 ± 0.146 0.715 ± 0.148 0.822 ± 0.154*,** <0.001
Hb (g/dl) 13.5 ± 1.9 13.5 ± 1.8 13.5 ± 2.0 13.6 ± 1.5 0.934
Ht (%) 40.6 ± 5.5 40.7 ± 5.2 40.5 ± 6.0 41.0 ± 4.3 0.813
Fasting plasma glucose (mg/dl) 171.8 ± 53.4 168.5 ± 50.8 166.2 ± 51.8 193.6 ± 56.8*,*** 0.005
Mean daily blood glucose (mg/dl) 217.6 ± 61.8 212.7 ± 57.9 214.4 ± 60.1 234.4 ± 69.6 0.092
AUC daily blood glucose 2785 ± 821 2756 ± 805 2731 ± 765 3010 ± 997 0.171
Hemoglobin A1c (%) (mmol/mol) 9.3 (78.6) ± 2.3 (25.6) 8.6 (70.9) ± 1.8 (20.1) 9.4 (79.6) ± 2.5 (26.9) 10.0 (85.4) ± 2.3 (25.2)** 0.007
Glycoalbumin (%) 26.0 ± 8.4 22.9 ± 5.9* 26.6 ± 9.0 27.8 ± 8.3** 0.003
Systolic blood pressure (mmHg) 126.8 ± 19.3 132.6 ± 24.0 124.4 ± 17.9 125.9 ± 14.8 0.107
Diastolic blood pressure (mmHg) 77.6 ± 13.1 79.4 ± 13.1 77.4 ± 12.9 75.6 ± 14.0 0.515
Total cholesterol (mg/dl) 190.9 ± 41.5 188.1 ± 40.1 191.8 ± 41.6 191.6 ± 43.6 0.829
LDL cholesterol (mg/dl) 115.9 ± 35.0 118.2 ± 36.2 114.6 ± 34.2 117.0 ± 36.4 0.767
HDL cholesterol (mg/dl) 47.2 ± 14.5 45.0 ± 10.6 47.8 ± 16.0 48.3 ± 13.5 0.364



















Fig. 1 Daily glucose profiles at baseline and on the day before 
discharge among the three groups. Values are presented as the 
mean ± SD. *p < 0.01 vs. baseline.  I at admission,  
D at admission,  N on the day before discharge,  N at 
admission,  I on the day before discharge,  D on the 
day before discharge
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at baseline or on the day before discharge. BP also did not 
differ among the three groups at both times. However, ΔHb 
and ΔHt (difference from baseline to the day before dis-
charge) were larger in group D than in group I, and ΔHb was 
also larger in group N than in group I (Fig. 2). Since base-
line glycemic control markers (such as HbA1c or GA) and 
ΔHb or ΔHt may be associated with short-term changes of 
CIMT, binary logistic regression analysis was performed to 
assess the relationship of baseline CIMT, baseline HbA1c, 
and Hb at baseline or on the day before discharge with the 
decrease of CIMT (ΔCIMT ≤ −0.04 mm or not) or increase 
of CIMT (ΔCIMT ≥ 0.04 mm or not), and the results are 
shown in Table  3. Baseline CIMT and Hb were positively 
correlated with a decrease of CIMT, while Hb on the day 
before discharge was negatively correlated with a decrease 
of CIMT. Conversely, baseline HbA1c and Hb were nega-
tively correlated with an increase of CIMT, while Hb on 
the day before discharge was positively correlated with an 
increase of CIMT.
In a post hoc power analysis, we had 57  % (between 
group I and group N) and 51  % (between group D and 
group N) statistical power to detect a CIMT difference.
Discussion
Three main findings were obtained in the present study. 
First, CIMT increased or decreased in diabetic patients 
undergoing stabilization of glycemic control even in a 
short period of 2 weeks, and the extent of change could 
be much larger than the estimated annual increase. Sec-
ond, baseline FPG and HbA1c levels were highest in 
group D among the three groups, but the daily glucose 
profile at baseline and on the day before discharge was 
not related to the change of CIMT. Third, a decrease of 
CIMT was associated with a larger baseline CIMT and 
a decrease of Hb during admission, while an increase of 
CIMT was associated with a lower baseline HbA1c and 
minimal change of Hb during admission.
The daily glucose profile, BP, and plasma lipids did not 
differ among the three groups during admission, suggest-
ing that there was no contribution of these factors to the 
change of CIMT in the present study. However, base-
line FPG and HbA1c were highest in group D, and base-
line HbA1c was positively correlated with a decrease of 
CIMT. Although Hb was not different among the three 
groups both at baseline and on the day before discharge, 
baseline Hb was positively correlated with a decrease of 
CIMT and discharge Hb was negatively correlated with 
a decrease of CIMT (Table  3). Thus, a higher baseline 
HbA1c and a greater decrease of Hb during admission 
were associated with a decrease of CIMT. The decrease 
of Hb was positively correlated with the baseline HbA1c 
level according to univariate analysis (r = 0.31, p < 0.001), 
suggesting that chronic hyperglycemia-induced osmotic 
diuresis may lead to dehydration and elevation of Hb, 
which may decrease following alleviation of dehydration 
due to improvement of hyperglycemia. Thus, in patients 
with a higher HbA1c accompanied by dehydration, 
CIMT may decrease after attainment of good glycemic 
control. On the contrary, baseline Hb was positively cor-
related with an increase of CIMT, while Hb on the day 
before discharge and baseline HbA1c were negatively 
correlated with it (Table  3). Although baseline FPG, 
HbA1c, and AUCglu were not different between group 
I and group N, baseline GA (reflecting the glycemic 
state over 1–2  weeks) was lowest in group I among the 
three groups. ΔHb was also smallest in group I among 
the three groups (Fig. 2). These results suggest that mild 
hyperglycemia baseline and a smaller change of Hb 
were associated with an increase of CIMT. Although the 
mechanism of such an increase of CIMT is unclear, it is 
possible that mild hyperglycemia may induce slight ove-
rhydration and a decrease of Hb by hemodilution, which 
may be associated with a decrease of baseline CIMT, 
while normalization of hemodynamics by improvement 
Table 2 Clinical characteristics at baseline and discharge
Values are presented as the mean ± SD or number (%)
I increased IMT group, N unchanged IMT group, D decreased IMT group, Ht hematocrit
* p < 0.01 vs N, ** p < 0.01 vs I
Group Total I N D p value
CIMT at baseline (mm) 0.737 ± 0.154 0.724 ± 0.146 0.714 ± 0.149 0.821 ± 0.154*,** <0.001
CIMT on the day before discharge (mm) 0.738 ± 0.155 0.800 ± 0.166* 0.715 ± 0.148 0.731 ± 0.145 <0.001
Hb at baseline (g/dl) 13.5 ± 1.9 13.5 ± 1.8 13.5 ± 2.0 13.6 ± 1.5 0.934
Hb on the day before discharge (g/dl) 13.2 ± 1.7 13.4 ± 1.7 13.1 ± 1.8 13.0 ± 1.3 0.305
Ht at baseline (%) 40.6 ± 5.5 40.7 ± 5.2 40.5 ± 6.0 41.0 ± 4.3 0.813
Ht on the day before discharge (%) 39.6 ± 5.0 40.3 ± 4.9 39.5 ± 5.4 39.4 ± 3.7 0.447
AUC daily blood glucose at baseline 2785 ± 821 2756 ± 805 2731 ± 765 3010 ± 997 0.171
AUC daily blood glucose on the day before discharge 1892 ± 398 1846 ± 327 1899 ± 400 1936 ± 486 0.628
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of glycemic control during admission may return CIMT 
to the level before the onset of recent mild hyperglyce-
mia. It is well known that the Hb level shows fluctuation. 
In addition to hemodilution, various other factors can 
influence Hb, such as anemia of chronic disease, altera-
tions of iron stores, chronic blood loss, transfusion, vita-
min and mineral status, and seasonal effects [15–19]. 
However, these factors would affect the Hb over a long 
period considering that the lifespan of erythrocytes is 
about 120 days. Thus, the changes of Hb during our study 
period of <2 weeks may have been due to hemodilution 
rather than other factors.
Current ultrasound transducers have insufficient axial 
resolution to separate the intimal and medial layers 
of the carotid artery wall, which is why the combined 
intima and media thickness is measured clinically as the 
CIMT. Pignoli et  al. previously compared pathological 
and in vivo or in vitro B-mode ultrasound measurements 
using carotid artery autopsy samples from healthy sub-
jects [20]. They revealed that about 20  % of the CIMT 
is composed of the intimal layer and 80 % is made up of 
the medial layer, with the intima-media thickness (IMT) 
values from both in  vivo and in  vitro B-mode ultra-
sound measurement being consistent with the results 
of pathological examination. Some later reports have 
suggested that the far wall, but not the near wall, of the 
carotid artery should be assessed in ultrasound studies 
[21, 22]. While intimal thickening is generally caused by 
foam cells derived from macrophages or smooth mus-
cle cells infiltrating the subendothelial space and cap-
turing oxidized lipids, medial thickening is induced by 
smooth muscle hypertrophy and/or hyperplasia [21]. 
Although the exact mechanism leading to an increase of 
IMT in diabetic patients remains unclear, Kozakova et al. 
recently proposed that it may involve chronic hyper-
glycemia-related enhancement of arterial stiffness and 
Fig. 2 Comparison of the changes of Hb and hematocrit (Ht) among the three groups: a ΔHb, b ΔHt. Values are presented as the mean ± SD. ΔHb 
and ΔHt were obtained by subtracting the baseline value from that on the day before discharge
Table 3 Logistic regression analysis of factors affecting ΔCIMT
B partial regression coefficient, β standarized partial regression coefficient
CIMT decrease (Δ CIMT ≤ −0.04 mm) CIMT increase (Δ CIMT ≥ 0.04 mm)
B β p value B β p value
CIMT at baseline (mm) 4.458 0.686 0.000 −0.217 −0.033 0.827
Hb at baseline (g/dl) 0.496 0.936 0.016 −0.388 −0.732 0.041
Hb on the day before discharge (g/dl) −0.527 −0.895 0.018 0.542 0.92 0.007
HbA1c at baseline (%) 0.059 0.138 0.411 −0.179 −0.418 0.025
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consequent remodeling of the carotid media [11]. They 
suggested that chronic hyperglycemia induced a decline 
of arterial wall elasticity and enhanced stiffness, which 
may then promote adaptive medial thickening by smooth 
muscle changes, but this mechanism seems unlikely to 
explain the short-term CIMT changes observed in the 
present study.
Dehydration due to chronic severe hyperglycemia may 
lead to an increase of CIMT, while amelioration of dehy-
dration by improvement of hyperglycemia may restore 
the reversible portion of this increase. On the other hand, 
mild overhydration due to relatively mild hyperglycemia 
may decrease CIMT, while amelioration of this state may 
restore the reversible decrease of CIMT.
Although CIMT is a biomarker of subclinical atheroscle-
rosis, it can fluctuate over a short period due to changes 
of the blood glucose level or hemodynamics. Therefore, we 
should consider whether blood glucose and hemodynam-
ics are stable when assessing changes of CIMT.
The present study had several limitations. First, the 
sample size was small, because the post hoc power analy-
sis showed that this study does not have adequate power 
which would provide β error. Second, we have no data on 
healthy subjects. It would probably be difficult to detect 
short-term changes of CIMT in healthy subjects dur-
ing daily life because their basal CIMT is smaller than 
that of patients with diabetes. On the other hand, dehy-
dration induced by exercise would be likely to alter the 
CIMT, so it may be interesting to investigate whether 
there are any changes of CIMT after sustained exercise. 
Third, we did not differentiate between type 1 and type 2 
diabetes with respect to the onset, severity of complica-
tion, or prognosis. Fourth, we have no data about intra-
observer agreement because we only measured CIMT 
twice over 2 weeks. However, there was no inter-observer 
variation, because all carotid studies were performed 
by a single trained examiner and CIMT was automati-
cally determined by using analytical software. Fifth, we 
did not evaluate biochemical markers of hemodynamic 
changes, such as brain natriuretic peptide (BNP), plasma 
renin activity, plasma aldosterone, or fractional excretion 
of Na, and we did not assess physiological hemodynamic 
markers like local carotid artery blood flow, wave speed, 
or stroke volume. Thus, further large-scale studies that 
investigate such factors will be needed to confirm the 
above hypothesis.
Conclusions
CIMT may show plasticity in diabetic patients and 
can change after even 2  weeks when hyperglycemia is 
improved. This point should be considered when per-
forming assessment of baseline CIMT and CIMT pro-
gression in prospective studies of diabetic patients.
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